Warby Parker (WRBY) Total Non-Current Liabilities (2020 - 2026)
Warby Parker (WRBY) reported Total Non-Current Liabilities of $359.0 million for Q1 2026, up 9.67% on a YoY basis from $327.4 million in Q1 2025, and up 2.03% quarter-over-quarter from $351.9 million in Q4 2025.
Warby Parker (WRBY) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Warby Parker has reported Total Non-Current Liabilities for 7 years, with the latest figure at $359.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 9.67% year-over-year to $359.0 million; the trailing twelve-month figure through Mar 2026 stood at $359.0 million (up 9.67% YoY), and the FY2025 full-year result was $351.9 million, up 4.89% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $359.0 million, up from $351.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $359.0 million in Q1 2026, with the low at $258.2 million in Q2 2023.
- Historically, Total Non-Current Liabilities has averaged $296.6 million across 5 years, with a median of $280.4 million in 2022.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 81.31% — and 2023, when it slipped 1.12%.
- Warby Parker's Total Non-Current Liabilities stood at $280.4 million in 2022, then decreased by 1.12% to $277.3 million in 2023, then rose by 21.0% to $335.5 million in 2024, then rose by 4.89% to $351.9 million in 2025, then advanced by 2.03% to $359.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $359.0 million (Q1 2026), $351.9 million (Q4 2025), and $336.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 1.91 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 24.24 Bn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 17.13 Bn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 941.16 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 1.03 Bn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 8.65 Bn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 3.98 Bn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 2.10 Bn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 12.54 Bn |
| 10 | Warby Parker | 3.11 Bn | 2.82 Bn | 131.04 Mn | 359.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 359.03 Mn |
| Dec 31, 2025 | 351.88 Mn |
| Sep 30, 2025 | 335.95 Mn |
| Jun 30, 2025 | 339.28 Mn |
| Mar 31, 2025 | 327.39 Mn |
| Dec 31, 2024 | 335.47 Mn |
| Sep 30, 2024 | 300.22 Mn |
| Jun 30, 2024 | 287.72 Mn |
| Mar 31, 2024 | 275.53 Mn |
| Dec 31, 2023 | 277.26 Mn |
| Sep 30, 2023 | 268.91 Mn |
| Jun 30, 2023 | 258.18 Mn |
| Mar 31, 2023 | 259.96 Mn |
| Dec 31, 2022 | 280.39 Mn |
| Sep 30, 2022 | 264.37 Mn |
| Jun 30, 2022 | 259.60 Mn |
| Mar 31, 2022 | 261.57 Mn |
| Dec 31, 2021 | 154.65 Mn |
| Sep 30, 2021 | 165.33 Mn |
| Dec 31, 2020 | 133.33 Mn |